Clinical Trials
16 trialsNCT04513925 2026-06-03
SKYSCRAPER-03
Hoffmann-La Roche
Phase 3 Completed
NCT04619797 2026-06-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT04929223 2026-05-26
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05805501 2026-05-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05862285 2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT04665843 2026-05-05
SKYSCRAPER-09
Hoffmann-La Roche
Phase 2 Completed
NCT03563716 2026-05-04
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT05645692 2026-04-29
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT04300647 2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2 Completed
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated